Quarterly ResultNov 12, 2026, 04:52 PM
InspireMD Q3 Revenue Down 11.1% to $2.24M; FDA Approves CGuard Prime for TCAR
AI Summary
InspireMD, Inc. announced its financial and operating results for the third quarter ended September 30, 2026. A significant highlight was the FDA approval of the CGuard® Prime TransCarotid Stent System for TCAR procedures, which is expected to expand the U.S. addressable market. However, total revenue for the quarter decreased by 11.1% year-over-year to $2.24 million, impacted by a prior recall of a delivery system. The company reported a net loss of $9.76 million for the quarter. Despite the revenue decline, international revenue saw a 9.1% increase. The company also announced the appointment of a new Senior Vice President of Global Sales and Marketing.
Key Highlights
- InspireMD received FDA approval for CGuard® Prime for TCAR procedures, expanding U.S. market potential.
- Third quarter 2026 total revenue was $2.24M, a 11.1% decrease year-over-year.
- International revenue increased 9.1% to $2.21M in Q3 2026.
- U.S. revenue decreased to $32K in Q3 2026 due to a prior recall.
- Gross profit margin declined to 10.7% in Q3 2026 from 34.2% in Q3 2025.
- Net loss for Q3 2026 was $9.76M, or $0.12 per share, compared to a $12.71M loss in Q3 2025.
- Cash and cash equivalents and marketable securities totaled $19.25M as of September 30, 2026.
Price Impact
More from NSPR